Atara Biotherapeutics, Inc.
ATRA$41M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaTHOUSAND OAKS38 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
May 9, 2026
12wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 1 past
🎯PDUFANext
FDA PDUFA Date ATA188 (priority)
5/9/2026
For progressive multiple sclerosis. BLA filing. Extracted from SEC filing: 8-K
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
EBV-induced Lymphomas
EBV-specific T cells (EBV-CTLs)
EBV-induced Lymphomas
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) | Phase 2 | EBV-induced Lymphomas | - |
EBV-specific T cells (EBV-CTLs) | Phase 2 | EBV-induced Lymphomas | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
ATRA News